{"id":"https://openalex.org/W2562262017","doi":"https://doi.org/10.1159/000454818","title":"Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects","display_name":"Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects","alternate_titles":[],"publication_year":2016,"publication_date":"2016-12-16","ids":{"openalex":"https://openalex.org/W2562262017","doi":"https://doi.org/10.1159/000454818","mag":"2562262017","pmid":"https://pubmed.ncbi.nlm.nih.gov/27978511"},"language":"en","primary_location":{"id":"doi:10.1159/000454818","doi":"https://doi.org/10.1159/000454818","is_oa":false,"landing_page_url":"https://doi.org/10.1159/000454818","pdf_url":null,"source":{"id":"https://openalex.org/S106979888","display_name":"American Journal of Nephrology","issn_l":"0250-8095","issn":["0250-8095","1421-9670"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310317820","host_organization_name":"Karger Publishers","host_organization_lineage":["https://openalex.org/P4310317820"],"host_organization_lineage_names":["Karger Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American Journal of Nephrology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2562262017"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5071555943","display_name":"Tadao Akizawa","orcid":"https://orcid.org/0000-0002-6150-9201","observed_orcids":["https://orcid.org/0000-0002-6150-9201"]},"institutions":[{"id":"https://openalex.org/I119182057","display_name":"SHOWA Medical University","ror":"https://ror.org/04mzk4q39","country_code":"JP","type":"education","lineage":["https://openalex.org/I119182057"]},{"id":"https://openalex.org/I4210150022","display_name":"Graduate School of Health Care Sciences, Jikei Institute","ror":"https://ror.org/04fn52t03","country_code":"JP","type":"education","lineage":["https://openalex.org/I4210150022"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Tadao Akizawa","raw_affiliation_strings":["Graduate School of Health Care Sciences, Jikei Institute, Osaka, Japan","Division of Nephrology, Department of Medicine, Showa University School of Medicine,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Graduate School of Health Care Sciences, Jikei Institute, Osaka, Japan","institution_ids":["https://openalex.org/I4210150022"]},{"raw_affiliation_string":"Division of Nephrology, Department of Medicine, Showa University School of Medicine,","institution_ids":["https://openalex.org/I119182057"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051402210","display_name":"Yoshiharu Tsubakihara","orcid":"https://orcid.org/0000-0001-9703-9443","observed_orcids":["https://orcid.org/0000-0001-9703-9443"]},"institutions":[{"id":"https://openalex.org/I4210150022","display_name":"Graduate School of Health Care Sciences, Jikei Institute","ror":"https://ror.org/04fn52t03","country_code":"JP","type":"education","lineage":["https://openalex.org/I4210150022"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Yoshiharu Tsubakihara","raw_affiliation_strings":["Graduate School of Health Care Sciences, Jikei Institute, Osaka,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Graduate School of Health Care Sciences, Jikei Institute, Osaka,","institution_ids":["https://openalex.org/I4210150022"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036113498","display_name":"Masaomi Nangaku","orcid":"https://orcid.org/0000-0001-7401-2934","observed_orcids":["https://orcid.org/0000-0001-7401-2934"]},"institutions":[{"id":"https://openalex.org/I74801974","display_name":"The University of Tokyo","ror":"https://ror.org/057zh3y96","country_code":"JP","type":"education","lineage":["https://openalex.org/I74801974"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Masaomi Nangaku","raw_affiliation_strings":["Division of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, and"],"raw_orcid":"https://orcid.org/0000-0001-7401-2934","affiliations":[{"raw_affiliation_string":"Division of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, and","institution_ids":["https://openalex.org/I74801974"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Yukihiro Endo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115149","display_name":"GlaxoSmithKline (Japan)","ror":"https://ror.org/01j6sxy67","country_code":"JP","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210115149"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Yukihiro Endo","raw_affiliation_strings":["GlaxoSmithKline, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Tokyo, Japan","institution_ids":["https://openalex.org/I4210115149"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103408611","display_name":"Hiromu Nakajima","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115149","display_name":"GlaxoSmithKline (Japan)","ror":"https://ror.org/01j6sxy67","country_code":"JP","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210115149"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Hiromu Nakajima","raw_affiliation_strings":["GlaxoSmithKline, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Tokyo, Japan","institution_ids":["https://openalex.org/I4210115149"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Tomoko Kohno","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115149","display_name":"GlaxoSmithKline (Japan)","ror":"https://ror.org/01j6sxy67","country_code":"JP","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210115149"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Tomoko Kohno","raw_affiliation_strings":["GlaxoSmithKline, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Tokyo, Japan","institution_ids":["https://openalex.org/I4210115149"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Yukiko Imai","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115149","display_name":"GlaxoSmithKline (Japan)","ror":"https://ror.org/01j6sxy67","country_code":"JP","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210115149"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Yukiko Imai","raw_affiliation_strings":["GlaxoSmithKline, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Tokyo, Japan","institution_ids":["https://openalex.org/I4210115149"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029454889","display_name":"Natsumi Kawase","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115149","display_name":"GlaxoSmithKline (Japan)","ror":"https://ror.org/01j6sxy67","country_code":"JP","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210115149"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Natsumi Kawase","raw_affiliation_strings":["GlaxoSmithKline, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Tokyo, Japan","institution_ids":["https://openalex.org/I4210115149"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029463322","display_name":"Katsutoshi Hara","orcid":"https://orcid.org/0000-0002-2630-039X","observed_orcids":["https://orcid.org/0000-0002-2630-039X"]},"institutions":[{"id":"https://openalex.org/I4210115149","display_name":"GlaxoSmithKline (Japan)","ror":"https://ror.org/01j6sxy67","country_code":"JP","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210115149"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Katsutoshi Hara","raw_affiliation_strings":["GlaxoSmithKline, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Tokyo, Japan","institution_ids":["https://openalex.org/I4210115149"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079698562","display_name":"John J. Lepore","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John Lepore","raw_affiliation_strings":["GlaxoSmithKline, Collegeville, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Collegeville, PA, USA","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5014367124","display_name":"Alexander R. Cobitz","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alexander Cobitz","raw_affiliation_strings":["GlaxoSmithKline, Collegeville, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Collegeville, PA, USA","institution_ids":["https://openalex.org/I4210114143"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":5,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":5.933,"has_fulltext":false,"cited_by_count":108,"citation_normalized_percentile":{"value":0.96876179,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":97,"max":100},"biblio":{"volume":"45","issue":"2","first_page":"127","last_page":"135"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11534","display_name":"Erythropoietin and Anemia Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11534","display_name":"Erythropoietin and Anemia Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10291","display_name":"Dialysis and Renal Disease Management","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10452","display_name":"Iron Metabolism and Disorders","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/daprodustat","display_name":"daprodustat","score":1.0},{"id":"https://openalex.org/keywords/hypoxia-inducible-factor-prolyl-hydroxylase-inhibitor","display_name":"hypoxia-inducible factor prolyl hydroxylase inhibitor","score":0.9729999899864197},{"id":"https://openalex.org/keywords/anemia-of-chronic-kidney-disease","display_name":"anemia of chronic kidney disease","score":0.9459999799728394},{"id":"https://openalex.org/keywords/hemodialysis","display_name":"hemodialysis","score":0.8960000276565552},{"id":"https://openalex.org/keywords/hemoglobin-response","display_name":"hemoglobin response","score":0.8970000147819519},{"id":"https://openalex.org/keywords/erythropoietin","display_name":"erythropoietin","score":0.9269999861717224},{"id":"https://openalex.org/keywords/vascular-endothelial-growth-factor","display_name":"vascular endothelial growth factor","score":0.9940000176429749},{"id":"https://openalex.org/keywords/dose-dependent-effects","display_name":"dose-dependent effects","score":0.7269999980926514},{"id":"https://openalex.org/keywords/japanese-patients","display_name":"Japanese patients","score":0.7799999713897705}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8530720472335815},{"id":"https://openalex.org/C2778534260","wikidata":"https://www.wikidata.org/wiki/Q218706","display_name":"Erythropoietin","level":2,"score":0.8058242797851562},{"id":"https://openalex.org/C2778248108","wikidata":"https://www.wikidata.org/wiki/Q5445","display_name":"Anemia","level":2,"score":0.7482023239135742},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.736510157585144},{"id":"https://openalex.org/C2778917026","wikidata":"https://www.wikidata.org/wiki/Q43041","display_name":"Hemoglobin","level":2,"score":0.6378984451293945},{"id":"https://openalex.org/C2778653478","wikidata":"https://www.wikidata.org/wiki/Q1054718","display_name":"Kidney disease","level":2,"score":0.5580628514289856},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.5387225151062012},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.537043035030365},{"id":"https://openalex.org/C2778063415","wikidata":"https://www.wikidata.org/wiki/Q391744","display_name":"Hemodialysis","level":2,"score":0.5177068710327148},{"id":"https://openalex.org/C2780959883","wikidata":"https://www.wikidata.org/wiki/Q111146","display_name":"Hematocrit","level":2,"score":0.5049710869789124},{"id":"https://openalex.org/C2777025900","wikidata":"https://www.wikidata.org/wiki/Q29725","display_name":"Vascular endothelial growth factor","level":3,"score":0.4321511387825012},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4279683828353882},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.08240076899528503},{"id":"https://openalex.org/C167734588","wikidata":"https://www.wikidata.org/wiki/Q4356503","display_name":"VEGF receptors","level":2,"score":0.06489256024360657},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000740","descriptor_name":"Anemia","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D000740","descriptor_name":"Anemia","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D001463","descriptor_name":"Barbiturates","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D001463","descriptor_name":"Barbiturates","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004921","descriptor_name":"Erythropoietin","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005998","descriptor_name":"Glycine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D005998","descriptor_name":"Glycine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D005998","descriptor_name":"Glycine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D006435","descriptor_name":"Renal Dialysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006454","descriptor_name":"Hemoglobins","qualifier_ui":"Q000032","qualifier_name":"analysis","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007564","descriptor_name":"Japan","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D042461","descriptor_name":"Vascular Endothelial Growth Factor A","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D051436","descriptor_name":"Renal Insufficiency, Chronic","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D051436","descriptor_name":"Renal Insufficiency, Chronic","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D051436","descriptor_name":"Renal Insufficiency, Chronic","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":true},{"descriptor_ui":"D064799","descriptor_name":"Hypoxia-Inducible Factor-Proline Dioxygenases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D064800","descriptor_name":"Prolyl-Hydroxylase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D064800","descriptor_name":"Prolyl-Hydroxylase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1159/000454818","doi":"https://doi.org/10.1159/000454818","is_oa":false,"landing_page_url":"https://doi.org/10.1159/000454818","pdf_url":null,"source":{"id":"https://openalex.org/S106979888","display_name":"American Journal of Nephrology","issn_l":"0250-8095","issn":["0250-8095","1421-9670"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310317820","host_organization_name":"Karger Publishers","host_organization_lineage":["https://openalex.org/P4310317820"],"host_organization_lineage_names":["Karger Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American Journal of Nephrology","raw_type":"journal-article"},{"id":"pmid:27978511","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/27978511","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American journal of nephrology","raw_type":"Clinical Trial, Phase II"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/randomized-controlled-trial","display_name":"Randomized Controlled Trial"},{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[{"id":"https://openalex.org/G4018883650","display_name":null,"funder_award_id":"26111003","funder_id":"https://openalex.org/F4320334764","funder_display_name":"Japan Society for the Promotion of Science"}],"funders":[{"id":"https://openalex.org/F4320307773","display_name":"GlaxoSmithKline","ror":"https://ror.org/01xsqw823"},{"id":"https://openalex.org/F4320334764","display_name":"Japan Society for the Promotion of Science","ror":"https://ror.org/00hhkn466"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":24,"referenced_works":["https://openalex.org/W1131435031","https://openalex.org/W1976019480","https://openalex.org/W1998943227","https://openalex.org/W2005973637","https://openalex.org/W2040029744","https://openalex.org/W2046224330","https://openalex.org/W2061342616","https://openalex.org/W2065394018","https://openalex.org/W2087830638","https://openalex.org/W2100628130","https://openalex.org/W2106855201","https://openalex.org/W2116057714","https://openalex.org/W2116374020","https://openalex.org/W2124116160","https://openalex.org/W2134487085","https://openalex.org/W2136732413","https://openalex.org/W2152233370","https://openalex.org/W2159511914","https://openalex.org/W2171230374","https://openalex.org/W2206481924","https://openalex.org/W2268447664","https://openalex.org/W2309322850","https://openalex.org/W2520158967","https://openalex.org/W3149132779"],"related_works":["https://openalex.org/W2790701104","https://openalex.org/W2961921650","https://openalex.org/W2949897715","https://openalex.org/W4394817341","https://openalex.org/W2799655697","https://openalex.org/W2980991992","https://openalex.org/W4409834200","https://openalex.org/W4289785769","https://openalex.org/W3160185326","https://openalex.org/W4367302290"],"abstract_inverted_index":{"BACKGROUND:":[0],"Daprodustat":[1,202],"(GSK1278863)":[2],"is":[3],"an":[4],"oral":[5],"hypoxia-inducible":[6],"factor":[7,103],"prolyl":[8],"hydroxylase":[9],"inhibitor":[10],"being":[11,178],"developed":[12],"for":[13,70,158],"treatment":[14],"of":[15,25,112],"anemia":[16,32,56],"associated":[17],"with":[18,31,55,77,172,194],"chronic":[19],"kidney":[20],"disease":[21],"(CKD).":[22],"The":[23,218],"effect":[24],"daprodustat":[26,44,86],"in":[27,49,57,143,162,209,214,221,231],"Japanese":[28,50,215],"CKD":[29],"patients":[30,51],"has":[33],"not":[34],"been":[35],"previously":[36],"investigated.":[37],"METHODS:":[38],"We":[39],"evaluated":[40,220],"the":[41,117,144,173,222],"relationship":[42],"between":[43,71],"dose":[45,176],"and":[46,73,99,140,148],"hemoglobin":[47,78,121,134,210],"response":[48],"on":[52],"hemodialysis":[53],"(HD)":[54],"a":[58],"4-week,":[59],"phase":[60],"II,":[61],"double-blind,":[62],"placebo-controlled":[63],"study.":[64,118],"After":[65,130],"interrupting":[66],"their":[67],"erythropoiesis-stimulating":[68],"agent":[69],"2":[72],"8":[74,170,181],"weeks,":[75],"subjects":[76,115,192],"8.5-10.5":[79],"g/dL":[80,127,142,157],"were":[81,108,136,166,186],"randomized":[82,114],"to":[83,125,155,169,180,212],"placebo":[84,213],"or":[85,90],"4,":[87,145],"6,":[88,146],"8,":[89,147],"10":[91,149,174],"mg":[92,150,175,196,204],"orally":[93],"once":[94],"daily.":[95],"Hemoglobin,":[96],"erythropoietin":[97],"(EPO),":[98],"vascular":[100],"endothelial":[101],"growth":[102],"(VEGF)":[104],"levels":[105],"during":[106],"therapy":[107],"evaluated.":[109],"RESULTS:":[110],"Eighty-six":[111],"97":[113],"completed":[116],"Mean":[119],"baseline":[120],"ranged":[122],"from":[123],"9.68":[124],"9.92":[126],"across":[128],"groups.":[129],"4-week":[131],"administration,":[132],"mean":[133],"changes":[135,230],"-0.28,":[137],"-0.01,":[138],"0.54,":[139],"0.97":[141],"groups,":[151],"respectively,":[152],"as":[153],"compared":[154],"-1.41":[156],"placebo.":[159],"Dose-dependent":[160],"increase":[161,208],"plasma":[163],"EPO":[164,198,228],"concentration":[165],"observed":[167],"up":[168],"mg,":[171],"responses":[177],"similar":[179],"mg.":[182],"Plasma":[183],"VEGF":[184,233],"concentrations":[185],"minimally":[187],"changed,":[188],"even":[189],"though":[190],"5":[191],"treated":[193],"6-10":[195],"reached":[197],">500":[199],"mIU/mL.":[200],"CONCLUSION:":[201],"4-10":[203],"once-daily":[205],"produced":[206],"dose-dependent":[207],"relative":[211],"HD":[216],"subjects.":[217],"doses":[219],"study":[223],"have":[224],"moderately":[225],"increased":[226],"endogenous":[227],"without":[229],"circulating":[232],"levels.":[234]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2562262017","counts_by_year":[{"year":2026,"cited_by_count":12},{"year":2025,"cited_by_count":5},{"year":2024,"cited_by_count":7},{"year":2023,"cited_by_count":9},{"year":2022,"cited_by_count":10},{"year":2021,"cited_by_count":16},{"year":2020,"cited_by_count":19},{"year":2019,"cited_by_count":10},{"year":2018,"cited_by_count":13},{"year":2017,"cited_by_count":7}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2017-01-06T00:00:00"}
